Anavex Life Sciences (AVXL) risk factors, FY2025 10-K

Risks Related to our Company

1. 01We have had a history of losses and no revenue, which raises a risk regarding our ability to continue as a going concern in the future
2. 02We may be unable to raise additional capital when needed, which would force us to delay, reduce or eliminate our research and development activities52% rewritten
3. 03A decline in the price of our common stock could affect our ability to raise further working capital and adversely impact our operations and would severely dilute existing or future investors if we were to raise funds at lower prices32% rewritten

Risks Related to the Discovery and Development of Our Current and Future Product Candidates

1. 04The marketing approval process for pharmaceutical products is a lengthy, complex and highly regulated process and we cannot predict the outcome of any interactions with the regulatory authorities or when we will receive marketing approval, if at allNew
2. 05Obtaining and maintaining regulatory approval of blarcamesine or any future product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of those product candidates in other jurisdictionsNew
3. 06Our research and development plans will require substantial additional future funding which could impact our operations and financial condition
4. 07We analyze genomic data from clinical trials to identify biomarkers, which we use in the analysis of our clinical trials
5. 08The regulatory approval processes of the FDA, EMA and comparable foreign regulatory authorities are lengthy, time-consuming and inherently unpredictable, which could lead to our inability to generate product revenue
6. 09All but one of our clinical trials to date have been conducted outside the United States, and the FDA, EMA and other foreign regulatory authorities may not accept data from such trials
7. 10We have received Fast Track designation for one of our compounds and may seek such designation or breakthrough therapy and priority review for other compounds in the future. Fast Track designation or breakthrough therapy designation may not actually lead to a faster FDA review and approval process
8. 11We have received orphan drug designation for several of our compounds, but we may be unable to maintain any benefits associated with orphan drug designation, including market exclusivity
9. 12If we fail to demonstrate efficacy in our non-clinical studies and clinical trials our future business prospects, financial condition and operating results will be materially adversely affected
10. 13If a particular product candidate causes undesirable side effects, then we may be unable to receive regulatory approval of or commercialize such product candidate67% rewritten
11. 14The occurrence of any event or penalty described above may limit our ability to commercialize our compounds and generate revenue and could require us to expend significant time and resources in response or generate negative publicity69% rewritten
12. 15Material modifications in the methods of product candidate manufacturing may result in additional costs or delay64% rewritten
13. 16We have advanced our research and development efforts on the treatment of neurodegenerative and central nervous system, or CNS, disorders, a field that has seen very limited success in product development76% rewritten
14. 17The use of any of our products in clinical trials may expose us to liability claims, which may cost us significant amounts of money to defend against or pay out, causing our business to suffer

Risks Related to our Business

1. 18We are highly dependent on our key personnel, and if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy
2. 19If we do not obtain the support of qualified scientific collaborators, our revenue, growth and profitability will likely be limited, which would have a material adverse effect on our business33% rewritten
3. 20We may not be able to develop, market or generate sales of our products to the extent anticipated. Our business may fail and investors could lose all their investment in our Company
4. 21None of our potential drug compounds may reach the commercial market for a number of reasons and our business may fail76% rewritten
5. 22If we fail to compete successfully with respect to partnering, licensing, mergers, acquisitions, joint venture and other collaboration opportunities, we may be limited in our ability to research and develop our potential drug compounds
6. 23In the course of our business, we, or third parties upon whom we rely, may gather, collect, receive, use, transmit, store/retain or dispose of data and confidential information (such as confidential employee information or health-related data), sensitive data, intellectual property and trade secrets68% rewritten
7. 24Our business could be affected by litigation, government investigations and enforcement actionsNew
8. 25Changes in U.S. and international trade policies may adversely impact our business and operating resultsNew
9. 26A variety of risks are associated with operating our business internationally which could materially adversely affect our business
10. 27Our ability to use our net operating loss (“NOL”) carryforwards and certain tax credit carryforwards may be subject to limitation47% rewritten
11. 28We are subject to healthcare laws and regulations which may require substantial compliance efforts and could expose us to criminal sanctions, civil and administrative penalties, contractual damages, reputational harm and diminished profits and future earnings, among other penalties
12. 29We expect current and future legislation affecting the pharmaceutical industry, including drug pricing reform, to impact our business generally, which could adversely affect our business operations62% rewritten
13. 30The coverage and reimbursement status of newly approved products is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for our product candidates, if approved, could limit our ability to market those products and decrease our ability to generate product revenue

Risks Related to our Common Stock

1. 31If we issue additional shares of common stock in the future, it will result in the dilution of our existing stockholders and may cause the share price of our common stock to fall
2. 32Our stock price has been volatile and may be volatile in the future
3. 33Our common stock may become the target of a “short squeeze.”62% rewritten

Risks Related to our Intellectual Property

1. 342. Because of the time, money and effort involved in obtaining and enforcing patents, our management may spend less time and resources on developing potential drug compounds than they otherwise would, which could increase our operating expenses and delay product programs
2. 356. If a court decides that an Anavex compound, its method of manufacture or use, infringes on a competitor’s patent, we may have to pay substantial damages for infringement
3. 368. Redesigning our potential drug compounds so that they do not infringe on other patents may not be possible or could require substantial funds and time
4. 37We may also support and collaborate in research conducted by government organizations, hospitals, universities or other educational institutions. These research partners may be unable or unwilling to grant us exclusive rights to technology or products derived from these collaborations
5. 38Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time
6. 39If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose intellectual property rights that are important to our business
7. 40Third-party claims of intellectual property infringement may prevent or delay our development and commercialization efforts
8. 41If we are unable to protect the confidentiality of our trade secrets, the value of our technology could be materially adversely affected and our business would be harmed
9. 42We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers
10. 43We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time consuming and unsuccessful and could harm our business
11. 44We may be subject to claims challenging the inventorship of our patents and other intellectual property
12. 45Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements
13. 46We may not be able to protect our intellectual property rights throughout the world
14. 47Changes in patent law could diminish the value of our patents and patent applications in general, thereby impairing our ability to protect our product candidates